Recombinant Protein Market Size Is Elastomers to Grow By 6.2% CAGR by 2025 | Global Industry Demand by Product, Application, Diagnostic Services and Treatment
Recombinant Protein Market – Insights
Recombinant proteins are used in development of novel therapies for severe chronic diseases such as cancer and other rare diseases. Recombinant protein production requires a special technique known as recombinant DNA (rDNA) technology. Depending on the type of the protein, recombinant proteins are classified into hormones, growth factor, cytokines, plasma protein factor, recombinant metabolic enzymes, and others. Manufacturers such as Biocon, Ltd., Eli, Lilly, and Company, Genentech, Inc., Novo Nordisk Pharmatech A/S, Prospec-Tany Technogene Ltd., Abcam plc, and BPS Bioscience, Inc. offer recombinant proteins for various applications such as drug discovery and development. Advancements in rDNA technology such as Clustered regularly interspaced short palindromic repeats (CRISPR) technique has complemented recombinant protein production. Furthermore, advancements in associated processes such as protein purification methods, alternative expression technologies, development of alternative cell lines, and enhanced cell culture systems have simplified and optimized the recombinant protein production processes.
Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1516
Increasing research & development expenditure on biologic drugs is expected to boost demand for recombinant proteins for research purposes
Biopharmaceutical organizations are focusing on research and development of novel biosimilars for life threatening diseases such as cardiovascular diseases, cancer, metabolic disorders such as diabetes, and certain rare conditions such as hemophilia. According to Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority was by all biopharmaceutical companies in the U.S. Rare disease medical space holds potential as there is relatively low competition. This is owing to less understanding of the disease progression pathways and entities. Therefore, companies could focus on R&D for development of biologics and subsequently biosimilars in this space. Some of the biosimilars available in the market include Eprex, manufactured by Janssen-Cilag Pty Ltd., which has been successful in treatment of anemia. Demand for biosimilars is increasing significantly, owing to high prices of biologics, in turn leading to high demand for recombinant protein.
The global recombinant protein market was valued at US$ 347.2 million in 2016 and is expected to witness a robust CAGR of 6.2% over the forecast period (2017–2025).
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1516
Figure 1. Global Recombinant Protein Market Share, by Application (%) 2017 and 2025
Technological advancement in production of recombinant protein is expected to fuel growth of the recombinant protein market
Advancement in technologies in various areas associated with or facilitating recombinant protein production have supported growth of recombinant protein market. For instance, development of alternative expression technologies such as mammalian cell expression, baculovirus expression, and E.coli expression, development of alternative cell lines, and enhanced cell culture systems have simplified and optimized recombinant protein processes. Furthermore, advanced chromatography protein purification methods such as FPLC and HPLC help in providing highly purified clinical grade recombinant proteins. Clustered regularly interspaced short palindromic repeats (CRISPR) technique is a genome editing technique used to target destruction in human cells and can improve recombinant protein production. Moreover, advancements in bioreactor systems have improved the product’s output within shorter time. According to National Centre for Biotechnology Information (NCBI), in 2014, about 65.6% of clinical scale manufacturers and 42% of commercial manufacturers adopted single use bioreactor for improvement in their bioprocessing.
However, factors such as complex manufacturing process, high costs, and requirement of high quality of these products (responsible for high costs) are expected to hinder growth of the market over the forecast period.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/recombinant-protein-market-to-surpass-us-5934-million-threshold-by-2025-globally-843
Some major players operating in the recombinant protein market include Crown Bioscience, Inc., ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Sigma Aldrich Company Ltd., Novoprotein Scientific, PeproTech, Inc., Feldan Bio, Inc., BioVision, Inc., HumanZyme, Inc., and GenScript Biotech Corporation.
Detailed Segmentation:
- Global Recombinant Protein Market, By Product Type:
- Hormones
- Growth Factor
- Cytokines
- Plasma Protein Factor
- Recombinant Metabolic Enzymes
- Immune Checkpoint Regulators
- Others
- Global Recombinant Protein Market, By Application:
- Drug Discovery & Development
- Biopharmaceutical Production
- Basic Research
- Others
- Global Recombinant Protein Market, By End User:
- Biopharmaceutical Companies
- Academic & Research Institutes
- Contract Research Organizations
- Others
- Global Recombinant Protein Market, By Geography:
- North America
- By Product Type:
- Hormones
- Growth Factor
- Cytokines
- Plasma Protein Factor
- Recombinant Metabolic Enzymes
- Immune Checkpoint Regulators
- Others
- By Application:
- Drug Discovery & Development
- Biopharmaceutical Production
- Basic Research
- Others
- By End User:
- Biopharmaceutical Companies
- Academic & Research Institutes
- Contract Research Organizations
- Others
- By Country:
- U.S.
- Canada
- By Product Type:
- Europe
- By Product Type:
- By Application:
- By End User:
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type:
- By Application:
- By End User:
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Product Type:
- By Application:
- By End User:
- By Country:
- Brazil
- Mexico
- Rest of Latin America
- Middle East
- By Product Type:
- By Application:
- By End User:
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type:
- By Application:
- By End User:
- By Country:
- Central Africa
- South Africa
- North Africa
- North America
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
